Navigation Links
Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial
Date:1/31/2008

in Ann Arbor, Michigan, and the Mayo Clinic in Rochester, Minnesota.

The trial (REO 014) is a Phase II, open-label, single agent study whose primary objective is to measure tumour responses and duration of response, and to describe any evidence of antitumour activity of intravenous, multiple dose REOLYSIN(R) in patients with bone and soft tissue sarcomas metastatic to the lung. REOLYSIN(R) is delivered intravenously to patients at a dose of 3x10(10) TCID(50) for five consecutive days. Patients may receive additional five-day cycles of therapy every four weeks for a maximum of eight cycles. Up to 52 patients will be enrolled in the study.

Eligible patients must have a bone or soft tissue sarcoma metastatic to the lung deemed by their physician to be unresponsive to or untreatable by standard therapies. These include patients with osteosarcoma, Ewing sarcoma family tumours, malignant fibrous histiocytoma, synovial sarcoma, fibrosarcoma and leiomyosarcoma.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com

This press release contains forward-looking statements, within the

meaning of Section 21E of the Securities Exchange Act of 1934, as

amended. Forward-looking statements, including the Company's expectations

related to the U.S. Phase II sarcoma clinical trial and the Company's

belief as to the potential of REOLYSIN(R) as a cancer therapeutic,

involve known and unknown risks and uncertainties, which could cause the

Company's ac
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 8th Canadian Patent
2. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Cyclophosphamide Treatment
3. Oncolytics Biotech Inc. Announces Filing of Phase 1/2 Clinical Trial with REOLYSIN(R)
4. Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Phase Ia/Ib Combination REOLYSIN(R)/Radiation Clinical Trial
5. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
6. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
7. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
10. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
11. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... at the Institute for Molecular Medicine Finland (FIMM), ... developed a novel "man and machine" decision support ... aid was described in PLOS One ... based on computer vision algorithms similar to those ... of only the diagnostically most relevant areas. Tablet ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 ... Fertilizer Industry” is a professional and in-depth ... The report provides basic Seaweed Fertilizer information, ... industry chain structure as well as industry ... analysis, including domestic market as well as ...
(Date:8/21/2014)... 21, 2014 His Majesty Willem-Alexander, King ... The Court of His Majesty Willem-Alexander, King of the ... Grand Opening of POET-DSM Advanced Biofuels’ Project LIBERTY cellulosic ... , The King will take part in the Grand ... for 11 a.m.-12:20 p.m. and tour the plant. POET-DSM ...
(Date:8/21/2014)... The College of New Rochelle announced today ... Mid-Hudson Region to be designated as a START-UP NY ... qualified “high-technology” businesses that align with the College’s academic ... been selected for the START-UP NY program and extremely ... economic development in New York by growing business and ...
Breaking Biology Technology:A novel 'man and machine' decision support system makes malaria diagnostics more effective 2Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 2Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 3His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 3The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3
... and Electric (MG&E) awarded Intergraph Mapping ... upgrade its existing FRAMME-based AM/FM/GIS application to G/Technology, ... scheduled for May. , ,G/Technology will provide MG&E ... environment and includes solutions designed to streamline everyday ...
... on the Midwest technology job market today, youve learned ... learned something about interviewing, thank-you letters and follow-up calls ... an older job seeker, though, you may have run ... your search: your age. Wait. Isn't age discrimination illegal? ...
... Firstlogic, Inc. announced the general availability ... Postalsoft Business Edition is designed to help organizations ... in the necessary order and format to receive ... , ,The program includes features designed to decrease ...
Cached Biology Technology:How 40-plus tech job seekers can prevent age discrimination 2How 40-plus tech job seekers can prevent age discrimination 3How 40-plus tech job seekers can prevent age discrimination 4
(Date:8/21/2014)... of the water window? It consists of radiations in ... absorbed by the water in biological tissues. New theoretical ... radiations within the water window. These could be the ... image of the biological samples or to be used ... the physical mechanism needed to efficiently generate the harmonic ...
(Date:8/21/2014)... University (ANU) team has successfully replicated one of the ... systems powered by sunlight which could manufacture hydrogen as ... sunlight. It is an exciting prospect to use them ... said Dr Kastoori Hingorani, from the ARC Centre of ... of Biology. , Hydrogen offers potential as a zero-carbon ...
(Date:8/20/2014)... Institute (HCI) at the University of Utah have identified ... BCR-ABL, the unregulated enzyme driving the blood cancer chronic ... nearly 6,000 new cases of CML will be diagnosed ... kinase inhibitors (TKIs), target BCR-ABL and are effective at ... control it in a way that allows patients to ...
Breaking Biology News(10 mins):Water window imaging opportunity 2Water and sunlight the formula for sustainable fuel 2Blueprint for next generation of chronic myeloid leukemia treatment 2
... doesn,t kill in the prostate it,s only once the ... fatal. Previous studies have shown that loss of the protein ... Cancer Center study published this week in the Journal ... switch that regulates the production of E-Cadherin: the transcription factor ...
... Biologists from the Ruhr-Universitt Bochum have explored how to ... the journal " Molecular and Cellular Neuroscience " they ... P, ensures the survival of motor neurons in culture. ... the molecule Brain Derived Neurotrophic Factor (BDNF), which was ...
... reprogram cancer cells that is, if these nucleic acids ... Cancer Center study published today in the journal Therapeutic ... into cancer cells. "There are many promising therapeutic ... cell membranes on their own, delivery to cancer cells has ...
Cached Biology News:Landmark study describes prostate cancer metastasis switch 2Vitamin P as a potential approach for the treatment of damaged motor neurons 2Cholesterol rafts deliver drugs inside cancer cells 2
Recombinant Porcine IL-1 alpha/IL-1F1, CF...
... siSolutions siRNA Custom Synthesis ... effective duplex RNA to knockdown ... 21-mers (19 RNA base pairs ... recently-published 27-mers, or other lengths ...
Tracker Datamatrix RS-1* reads 96 2D Bar-coded tubes within 20 seconds....
Complete cell culture media with cytokines...
Biology Products: